GEO series

Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema

GSE279422 Homo sapiens (human) RNA-seq (gene expression) 43 samples Submitted 2026/01/24 Platform GPL24676

At a glance

RNA-seq (gene expression) · human · 43 samples

What it is: RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
Organism: Homo sapiens (human)
Samples: 43 samples: 43 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
Data you can get: A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Paper: Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand EczemaAllergy · 2026

Summary (written by the submitters)

Chronic hand eczema (CHE) is a painful, itchy and inflammatory skin disease of multifactorial origin. CHE can be categorized based on etiology and/or clinical presentation, including intertwined atopic-contact eczema-psoriasis traits, making it challenging to diagnose and treat. While being the most frequent work-related dermatosis, the underlying immune mechanisms remain unclear.

Read the full summary ↓

Here we performed a randomized controlled study comparing dupilumab and placebo and demonstrated that CHE is a type 2 immunity driven disease, regardless of etiological factors or clinical presentation. We conducted a comprehensive molecular profiling of CHE patients of all etiologies and morphologies to identify potential common features and evaluated the consequences of blocking IL-4Rα during 16 weeks. This phase 2b randomized, multicenter, double-blind, placebo-controlled clinical trial included 94 adults with moderate to severe CHE persisting for at least six months and resistant to potent topical corticosteroids. We found that CHE patients share complex transcriptomic signatures with those of atopic dermatitis and psoriasis patients, with dysregulated genes involved in skin barrier, leukocyte migration, cytotoxicity, type 1, 2 and 3 immunity. Compared to placebo control, 16-week dupilumab treatment significantly improved clinical severity and quality of life of CHE patients, while largely restoring appropriate transcriptomic and proteomic programs related to skin barrier and immune homeostasis. These findings demonstrate that IL-4Rα signaling is a critical regulator of CHE pathological features, independent of atopic dermatitis background or environmental triggers, and propose reclassifying CHE as a type 2 immune disorder, with dupilumab or IL-4/13 targeted therapy as the mainstay treatment for moderate to severe disease.

Published in

Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema

Gery P, Ekren R, Bérard E et al. · Allergy 2026 · PMID 41705342 · doi:10.1111/all.70263

This dataset

Open GSE279422 in finder → Find more human RNA-seq datasets →

Download · which file do I need?

Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

Series matrix ↓

2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE279422_RAW.tar (it can run to tens of gigabytes).

All supplementary files ↗ Whole study · RAW.tar ↓

3 · Start from the raw reads

Raw sequencing reads

The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.

Raw reads on ENA ↗

What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.

Also filed as BioProject PRJNA1172682 and SRA study SRP538462. Searching any of these in the dataset finder brings you back here.

NCBI GEO page ↗ Paper (PMID 41705342) ↗

Study design

43 samples, each with a distinct title — no replicated groups

Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.

How we read this: Read from 43 sample titles: 43 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.

Samples in this study

GSM8569726 P1, week 0, Placebo
GSM8569727 P1, week 16, Placebo
GSM8569728 D1, week 0, Dupilumab
GSM8569729 D1, week 16, Dupilumab
GSM8569730 P47, week 0, Placebo
GSM8569731 D2, week 0, Dupilumab
GSM8569732 D2, week 16, Dupilumab
GSM8569733 D4, week 0, Dupilumab
GSM8569734 D4, week 16, Dupilumab
GSM8569735 D5, week 0, Dupilumab
GSM8569736 D5, week 16, Dupilumab
GSM8569737 D6, week 0, Dupilumab
GSM8569738 D6, week 16, Dupilumab
GSM8569739 P2, week 0, Placebo
GSM8569740 P2, week 16, Placebo
GSM8569741 D8, week 0, Dupilumab
GSM8569742 D8, week 16, Dupilumab
GSM8569743 P3, week 0, Placebo
GSM8569744 P3, week 16, Placebo
GSM8569745 P4, week 0, Placebo
GSM8569746 P4, week 16, Placebo
GSM8569747 D10, week 0, Dupilumab
GSM8569748 D10, week 16, Dupilumab
GSM8569749 P6, week 0, Placebo
GSM8569750 P6, week 16, Placebo
GSM8569751 P9, week 0, Placebo
GSM8569752 D12, week 0, Dupilumab
GSM8569753 D12, week 16, Dupilumab
GSM8569754 C1, control
GSM8569755 C2, control
GSM8569756 C3, control
GSM8569757 C4, control
GSM8569758 C5, control
GSM8569759 C6, control
GSM8569760 C7, control
GSM8569761 C8, control
GSM8569762 C9, control
GSM8569763 C10, control
GSM8569764 C11, control
GSM8569765 C12, control

+ 3 more — browse all 43 samples with per-sample file links →

Datasets on a similar topic

GSE264314 Topical application of Urolithin A slows intrinsic skin aging and protects from UVB-mediated photodamage: Findings from Randomized Clinical Trials 57 samples shares clinical, trial
GSE299759 An integrated clinical genomic and transcriptomic subgrouping of central chondrosarcoma 54 samples shares integrated, clinical
GSE316195 A Phase 1 clinical trial and single-cell correlates of motixafortide, cemiplimab, gemcitabine and nab-paclitaxel for metastatic treatment-naïve metastatic pancreatic ductal adenocarcinoma. 22 samples shares clinical, trial
GSE279852 Single-cell RNA-sequencing of undifferentiated pleomorphic sarcoma, myxofibrosarcoma, and liposarcoma samples from patients participating in a clinical trial studying BO-112 plus Nivolumab and hypofractionated pre-operative radiotherapy. 10 samples shares clinical, trial
GSE217707 Single-cell sequencing analysis reveals the tissue architecture and empowers clinical trial in advanced conjunctival melanoma 10 samples shares clinical, trial
GSE291286 Clinical cure of chronic hepatitis B is associated with priming and perpetuation of hepatic CD4+ T cell responses 98 samples shares clinical, chronic
GSE279781 CD137 agonism enhances anti-PD1 induced activation of clonally expanded CD8+ T cells in a neoadjuvant pancreatic cancer clinical trial 30 samples shares clinical, trial
GSE280063 Clinical and Immunological Outcomes after Randomized Trial of Baked Milk Oral Immunotherapy for Milk Allergy 24 samples shares clinical, trial

Search all human RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.